Showing 7731-7740 of 9460 results for "".
- U.S FDA Clears EndyMed’s Hair Removal Devicehttps://practicaldermatology.com/news/fda-clears-endymeds-hair-removal-device/2461393/The US Food and Drug Administration has cleared Endymed Ltd’s Pure Laser hair removal device for the marketing and sales. The Pure Laser was developed in the Company's labs by its subsidiary Endymed Medical Ltd. The Company intends to commence marketing in the US th
- Game Changer: Incyte’s Ruxolitinib Reverses Vitiligohttps://practicaldermatology.com/news/game-changer-incytes-ruxolitinib-reverses-vitiligo/2461392/Topical Ruxolitinib is highly effective for skin re-pigmentation in vitiligo, according to Phase III clinical trial results published in The New England Journal of Medicine. The study showed better than 75 percent improvement on face and 50 percent improvement on body fo
- Aesthetics Biomedical's Vivace Ultra Wins FDA Clearancehttps://practicaldermatology.com/news/aesthetics-biomedicals-vivace-ultra/2461390/The FDA has given the nod to Aesthetics Biomedical Inc.’s Vivace Ultra for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. An innovative reimagination and technical upgrade of the legacy Vivace Microneedle RF device, the Vivace Ultra comb
- Skin Microbiome Linked to GVHD Following Stem Cell Transplant in Leukemiahttps://practicaldermatology.com/news/skin-microbiome-linked-to-gvhd-following-stem-cell-transplant-in-leukemia/2461385/Organ damage occurs in up to 70 percent of patients in the first few months following stem cell transplant, but the precise reasons for this potentially life-threatening reaction haven’t been fully understood. Now, researchers led by Georg Stary from the Department of Dermatology at MedUni
- Castle Bioscience’s DecisionDx-SCC Test Boosts Mohs Surgeons' Confidencehttps://practicaldermatology.com/news/castle-biosciences-decisiondx-scc-test-boosts-mohs-surgeons-confidence/2461382/Castle Bioscience’s DecisionDx-SCC test results can assist Mohs surgeons in making risk-aligned management plans and increase confidence in their treatment decisions, according to data presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. DecisionD
- ASDSA's 2022 Top Advocates Recognizedhttps://practicaldermatology.com/news/asdsas-2022-top-advocates-recognized/2461381/Meet the American Society for Dermatologic Surgery Association (ASDSA) honorees from the fourth annual Top Advocate program Honorees are chosen based on their contribution to various advocacy efforts throughout the year and demonstrated commitment to patient safety in the field of derma
- Crown's Skinpen Scores New Indications in the EU and UKhttps://practicaldermatology.com/news/crowns-skinpen-scores-new-indications-in-the-eu-and-uk/2461375/Crown Aesthetics’ SkinPen Precision scored three new approved indications in the EU and UK. The new&
- ASDS News: CellFX Clears Low-Risk Basal Cell Carcinoma Lesionshttps://practicaldermatology.com/news/asds-news-cellfx-clears-low-risk-basal-cell-carcinoma-lesions/2461374/CellFX procedure is effective for low-risk superficial and nodular basal cell carcinoma lesion clearance, according to research presented at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting. "It is exciting and encouraging to see complete clearance of b
- Galderma Debuts Sensitive Skincare Facultyhttps://practicaldermatology.com/news/galderma-debuts-sensitive-skincare-faculty/2461372/Reinforcing its commitment to advancing dermatology for every skin story, Galderma has formed a global Sensitive Skincare Faculty, which will focus its efforts on helping people with sensitive skin live better lives. The Faculty will focus on three key pillars of research, innovation, and engagem
- Candesant Biomedical Introduces New SweatTech Initiative at ASDShttps://practicaldermatology.com/news/candesant-biomedical-novel-investigational-technology-for-hyperhydrosis/2461371/Candesant Biomedical is introducing a new initiative – SweatTech™ – at the ASDS annual meeting. The company is also developing a new novel technology (currently under FDA review) that reduces axillary hyperhidrosis. Their “TAT” (targeted alkali thermolysis) pat